CL2022002431A1 - Formulaciones de liberación controlada que comprenden drotaverina o sal de la misma. - Google Patents

Formulaciones de liberación controlada que comprenden drotaverina o sal de la misma.

Info

Publication number
CL2022002431A1
CL2022002431A1 CL2022002431A CL2022002431A CL2022002431A1 CL 2022002431 A1 CL2022002431 A1 CL 2022002431A1 CL 2022002431 A CL2022002431 A CL 2022002431A CL 2022002431 A CL2022002431 A CL 2022002431A CL 2022002431 A1 CL2022002431 A1 CL 2022002431A1
Authority
CL
Chile
Prior art keywords
drotaverine
controlled release
release formulations
salt
provides
Prior art date
Application number
CL2022002431A
Other languages
English (en)
Inventor
Sushma Paul Berlia
Nishant Berlia
Gurvínder Singh
Sunder Singh Bhandari
Anupama Diwan
Original Assignee
Sushma Paul Berlia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sushma Paul Berlia filed Critical Sushma Paul Berlia
Publication of CL2022002431A1 publication Critical patent/CL2022002431A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona formulaciones de liberación controlada que comprenden Drotaverina o una de sus sales o agentes activos similares que son propensos a la degradación oxidativa/hidrolítica. La invención proporciona formulaciones de liberación controlada una o dos veces al día de Drotaverina o una sal de la misma que evita las fluctuaciones de los niveles plasmáticos, reduce la cantidad de píldoras y los efectos secundarios debido al programa de dosificación simplificado, mejorando así el cumplimiento del paciente. La invención también proporciona métodos de preparación de formulaciones de liberación controlada de Drotaverina o una de sus sales. La invención proporciona además formulaciones de liberación controlada de Drotaverina o sal de la misma para tratar al menos un síntoma de trastornos gastrointestinales, biliares, urológicos y ginecológicos caracterizados por estados espásticos de los músculos lisos en un sujeto.
CL2022002431A 2020-03-09 2022-09-06 Formulaciones de liberación controlada que comprenden drotaverina o sal de la misma. CL2022002431A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN202011010072 2020-03-09

Publications (1)

Publication Number Publication Date
CL2022002431A1 true CL2022002431A1 (es) 2023-03-03

Family

ID=75497970

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022002431A CL2022002431A1 (es) 2020-03-09 2022-09-06 Formulaciones de liberación controlada que comprenden drotaverina o sal de la misma.

Country Status (15)

Country Link
US (1) US20230018600A1 (es)
EP (1) EP4117638A1 (es)
JP (1) JP2023525202A (es)
KR (1) KR20220151678A (es)
CN (1) CN115279346A (es)
AU (1) AU2021235395A1 (es)
BR (1) BR112022017998A2 (es)
CA (1) CA3174747A1 (es)
CL (1) CL2022002431A1 (es)
CO (1) CO2022013429A2 (es)
CR (1) CR20220506A (es)
IL (1) IL296132A (es)
JO (1) JOP20220209A1 (es)
MX (1) MX2022011196A (es)
WO (1) WO2021181262A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230248718A1 (en) * 2022-02-09 2023-08-10 Sushma Paul BERLIA Pharmaceutical combination of antispasmodic and anxiolytic agent
WO2024023785A1 (en) 2022-07-29 2024-02-01 Berlia Sushma Paul A stable pharmaceutical oral liquid formulation of an antispasmodic agent

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU225779B1 (en) 1999-07-28 2007-08-28 Chinoin Gyogyszer Es Vegyeszet Pharmaceutical composition containing paracetamol and drotaverine and process for producing it
RU2199308C1 (ru) 2001-12-24 2003-02-27 Закрытое акционерное общество "Брынцалов-А" Раствор для инъекций нош-бра, обладающий спазмолитическим действием
FR2891459B1 (fr) * 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
GB2460915B (en) * 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
EP2156835A1 (en) 2008-08-19 2010-02-24 Sanofi-Aventis New therapeutic use of drotaverine
GB201003734D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
EA022944B1 (ru) 2011-05-20 2016-03-31 Хиноин Прайвит Ко Лтд. Фармацевтическая композиция, содержащая дротаверин
CA2835293C (en) * 2011-06-08 2020-08-18 Sti Pharma, Llc Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
RU2535049C1 (ru) 2013-07-11 2014-12-10 Общество с ограниченной ответственностью "КОМПАНИЯ "ДЕКО" Способ получения стабилизированной субстанции дротаверина гидрохлорида
RU2704613C2 (ru) 2014-11-11 2019-10-30 Д-Р Редди'С Лабораторис Лимитед Фармацевтические препараты с фиксированной комбинацией доз обезболивающего и антиспазматического агентов
WO2018015946A1 (en) * 2016-07-17 2018-01-25 Mapi Pharma Ltd. Extended release dosage forms of pregabalin
EP3520781A1 (en) 2018-02-05 2019-08-07 Adamed sp. z o.o. A pharmaceutical composition comprising metamizole, drotaverine, and caffeine

Also Published As

Publication number Publication date
BR112022017998A2 (pt) 2022-10-25
JP2023525202A (ja) 2023-06-15
CO2022013429A2 (es) 2022-09-30
MX2022011196A (es) 2022-09-19
JOP20220209A1 (ar) 2023-01-30
AU2021235395A1 (en) 2022-09-29
WO2021181262A1 (en) 2021-09-16
CA3174747A1 (en) 2021-09-16
CR20220506A (es) 2023-01-17
EP4117638A1 (en) 2023-01-18
KR20220151678A (ko) 2022-11-15
CN115279346A (zh) 2022-11-01
US20230018600A1 (en) 2023-01-19
IL296132A (en) 2022-11-01

Similar Documents

Publication Publication Date Title
CL2022002431A1 (es) Formulaciones de liberación controlada que comprenden drotaverina o sal de la misma.
UY34974A (es) Piridazina 1,4 disustituida, análogos de la misma y métodos para tratar las enfermedades relacionadas con deficiencia del smn
PA8637201A1 (es) Difenilimidazopirimidina e-imidazol aminas como inhibidores de la b-secretasa
ECSP22014980A (es) Regímenes de dosificación para inhibidores orales del factor d del complemento
CO2020013840A2 (es) Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados
AR093247A1 (es) Agente profilactico y/o terapeutico para sintomas conductuales y psicologicos asociados con la enfermedad neurodegenerativa o sintomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo
ECSP14013160A (es) Procedimiento para la fabricación de una composición farmacéutica en forma de tabletas de liberación prolongada conteniendo pirfenidona y su aplicación en la regresión de la insuficiencia renal crónica, contractura capsular mamaria y fibrosis hepatica hu
CL2010001260A1 (es) Composicion farmaceutica que comprende una sal de estroncio y vitamina d y una ciclodextrina, donde la relacion masica entre la cantidad de vitamina d y la cantidad de ciclodextrina esta comprendida entre 1/40 y 1/800, util para tratar o prevenir osteoporosis.
CO2024000588A2 (es) Composiciones y métodos para la inhibición de ras
BR112012011298A2 (pt) métodos de tratar ou previnir trombose de stent
AR088585A1 (es) Un medicamento para tratar la enfermedad del ojo anterior
CO6511222A2 (es) Derivado de idenona y composición famacéutica que comprende el mismo
ECSP22085221A (es) Pirrolopirimidinaminas como inhibidores del sistema del complemento
CO2022004281A2 (es) Métodos de tratamiento de la epilepsia utilizando dichos métodos
ECSP20078586A (es) Compuestos de azabencimidazol y productos farmacéuticos
CO2023012702A2 (es) Derivados de diazepina útiles en el tratamiento de clostridium difficile
AR114306A1 (es) Tratamiento y prevención de trastornos del sueño
ECSP12012352A (es) Agente terapéutico de liberación sostenida para la hipertensión y la disfunción renal
CO2021014968A2 (es) Composición para la prevención o el tratamiento de la caída del cabello que incluye hapln1
ECSP20080695A (es) Agente de prevención de la enfermedad de sigatoka y regulador del crecimiento vegetal para plantas musáceas
BR112021010856A2 (pt) Vibegron para o tratamento de sintomas de bexiga hiperativa
AR069521A1 (es) Sales de propionato de 3 (2,2,2- trimetilhidrazinio) para la profilaxis y el tratamiento de la ateroesclerosis y uso medico
AR121975A1 (es) Oligómeros antisentido de opa1 para tratamiento de afecciones y enfermedades
AR119548A1 (es) Regímenes de dosificación para inhibidores orales del factor d del complemento
ECSP088317A (es) Composiciones farmacéuticas para el tratamiento de trastornos del oído interno